Evidence map›Paper›PMID 41697393›Full record

ArticleCancer immunology, immunotherapy : CII2026

AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.

Kohei Hamada, Junzo Hamanishi, Akihiko Ueda, Shiro Takamatsu, Kosuke Yoshihara, Takayuki Nagasawa, Toshiyuki Seki, Akira Kikuchi, Etsuko Fujimoto, Mana Taki and 8 more

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kohei HamadaDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Junzo HamanishiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. jnkhmns@kuhp.kyoto-u.ac.jp.ORCID 0000-0002-7750-0623
Akihiko UedaDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Shiro TakamatsuDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Kosuke YoshiharaDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takayuki NagasawaDepartment of Obstetrics and Gynecology, Iwate Medical University, Yahaba, Japan.
Toshiyuki SekiDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Akira KikuchiDepartment of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.
Etsuko FujimotoDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Mana TakiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Koji YamanoiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Ryusuke MurakamiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Kazuki KumadaTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Muneaki ShimadaDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Aikou OkamotoDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Masaki MandaiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Noriomi MatsumuraDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Funding

Japan Society for the Promotion of Science 17H01587Japan Society for the Promotion of Science 18H02945
6 · The paper itself

Abstract

Transcriptomic classification methods have been proposed for ovarian clear cell carcinoma. However, their clinical significance and association with pathologically evaluated tumor-infiltrating lymphocytes (TILs) remain unclear. We established two large transcriptomic datasets and analyzed RNA-sequencing data from 189 (JGOG3025-TR1 cohort) and 38 (Kyoto cohort) ovarian clear cell carcinomas. Representative histopathological slides were also digitized (102 and 38, respectively). Cell types were classified by two state-of-the-art artificial-intelligence models, and TILs were quantified. The transcriptomically defined immune subtype was associated with significantly poor prognosis (hazard ratio, 2.54; 95% CI, 1.42-4.54; p = 0.002 for OS). However, this group also contained significantly higher proportion of advanced-stage cases (p = 0.003), and multivariate analyses showed no independent prognostic effect (hazard ratio, 1.32; 95% CI, 0.68-2.58; p = 0.42 for OS). In contrast, the pathologically defined inflamed group demonstrated a trend toward improved survival, and the inflamed phenotype emerged as a statistically significant favorable prognostic factor for both OS and PFS in multivariate analyses (hazard ratio, 0.32; 95% CI, 0.13-0.78; p = 0.013 for OS. hazard ratio, 0.32; 95% CI, 0.15-0.67; p = 0.0026 for PFS). These findings indicate a discordance between transcriptome- and pathology-based immune classifications and suggest greater prognostic relevance of pathology-derived immune status.

Indexed as

Adenocarcinoma, Clear CellArtificial IntelligenceLymphocytes, Tumor-InfiltratingOvarian NeoplasmsTranscriptomeFemaleGene Expression ProfilingHumansMiddle AgedPrognosisArtificial intelligenceDeep learningDigital pathologyOvarian cancerPrognosisTumor-infiltrating lymphocytes

Identifiers

PMID41697393
PMCPMC12909737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.